Antinuclear antibodies associated auto-immune cytopenia in childhood is a risk factor for systemic lupus erythematosus.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
accepted:
15
12
2023
received:
20
07
2023
revised:
12
12
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
aheadofprint
Résumé
Autoimmune cytopenia (AIC) in children may be associated with positive antinuclear antibodies (ANA) and may progress to systemic lupus erythematosus (SLE). We evaluated the risk of progression to SLE of childhood-onset ANA-associated AIC. In the French national prospective OBS'CEREVANCE cohort, the long-term outcome of children with ANA-associated AIC (ANA titer ≥ 1/160) and the subgroup of children who developed SLE were described. ANA were positive in 355/1803 (20%) children with AIC. With a median follow-up of 5.8 (0.1-29.6) years, 79/355 (22%) patients developed SLE at a median age of 14.5 (1.1-21.4) years; 20% of chronic immune thrombocytopenic purpura, 19% of autoimmune hemolytic anemia and 45% of Evans syndrome. No ANA-negative patients developed SLE. Severe manifestations of SLE were observed in 21 patients and 2 patients died. In multivariate analysis including patients with positive ANA within the first 3 months after AIC diagnosis, age > 10 years at AIC diagnosis (relative risk (RR): 3.67, 95% confidence interval (CI) 1.18; 11.4, P = 0.024) and ANA titer > 1/160 (RR: 5.28, 95% CI 1.20; 23.17, P = 0.027) were associated with the occurrence of SLE after AIC diagnosis. ANA-associated AIC is a risk factor for progression to SLE, especially in children with an initial ANA titer > 1/160 and an age > 10 years at AIC diagnosis. ANA screening should be recommended in children with AIC and ANA positive patients should be long-term monitored for SLE with a special attention on the transition period.
Identifiants
pubmed: 38227934
pii: 514595
doi: 10.1182/blood.2023021884
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 American Society of Hematology.